Abstract: Kryptofix ® 2.2.2 (Kry) or tetrabutylammonium (TBA) are commonly used as phase transfer catalysts in 18 F-radiopharmaceutical productions for positron emission tomography (PET). Due to their toxicity, quality control has to be performed before administration of the tracer to assure that limit concentration of residual reagent is not reached. Here, we describe the successful development and pharmaceutical validation (for specificity, accuracy and detection limit) of a simplified color spot test on TLC plates. We were able to prove its applicability as a general, time and resources saving, easy to handle and reliable method in daily routine analyzing 18 F-tracer formulations for Kry 
Introduction
Production of 18 in US Pharmacopoeia (USP) limit is <50 µg/mL [4] . For TBA in 18 F-radiopharmaceuticals a limit of 2.6 mg/V is defined in Ph. Eur. (see same monographs as for Kry). Ph. Eur. suggests a color spot test on a thin layer chromatography (TLC) plate for Kry and a HPLC method for TBA in 18 F-radiopharmaceutical monographs (see above).
In the past, various procedures have been described in the literature for identification and quantification of Kry, with the aim of providing specific and fast methods. TLC procedures are the most widespread, as they do not require sophisticated instrumental equipment. A color spot test on a TLC plate as used in monographs with iodoplatinate [5] for staining was described by Mock et al. [6] . To increase specificity and avoid false positive (e.g., from other amines) or false negative results (from stabilizers) thin layer chromatography systems were developed [7] [8] [9] [10] . But also gas chromatography (GC; [11] ), high-performance liquid chromatography (HPLC; [12] ) or liquid chromatography-tandem mass spectrometry (LC/MS/MS; [13] ) and even NMR or IR spectroscopy [14] were applied. More recently, a very fast (<1 min) and highly sensitive (lower limit = 0.5 ng/mL) rapid-resolution liquid chromatography MS/MS coupled system for analysis of Kry was p ublished [15] . Still, these methods suffer from certain disadvantages. The latter (GC, LC, MS, NMR, IR) need high-quality instrumental equipment combined with a higher effort for validation. On the other hand, TLC tests are more time consuming due to development of plates or require the expensive reagent iodoplatinate. In addition, in our opinion to prove that in a certain radiopharmaceutical formulation the Kry (or TBA) content is below a defined limit-without the necessity of exact quantification, the te st should be as simple and quick as possible, but nevertheless meeting pharmaceutical requirements. This particularly holds true in view of the fact that all literature data agree that, when synthesis and purification were performed successfully, Kry or TBA residues were extremely low and far from limits. When any test for Kry (or TBA) is applied to a newly produced radiopharmaceutical, it will always need some kind of validation, no matter how specific the test proved to be so far. Matrix effects may play an important role, pH as well. The important factor is how much time and effort it will take in daily routine.
After first promising results with the TLC spot tests as will be described below for Kry and TBA, we set up validations regarding specificity, accuracy and detection limit for [ 18 where residual N,N-dimethylaminoethanol (DMAE) may interfere [16] . As the HPLC procedure for TBA analysis described in the monographs appeared to be challenging, the spot test was also to be validated for this reagent, with [ 18 F]FLT as example [17] . As an additional important parameter, the stability of the necessary standard solutions containing the limit co ncentrations of Kry or TBA should also be investigated.
Experime ntal

General
All reagents were of highest purity available or of pharmaceutical grade, where necessary (article numbers in brackets) and were used as received. 0.6% NaCl and 0.7% disodium-hydrogencitrate in water for injection. pH was 5.0 ± 0.2 or was adjusted to pH 6.0 ± 0.2 with 1 N NaOH. Solutions were stored at 2.0-8.0 °C for a maximum of one week. Solutions (c)-(e) had a shelf life of 1 day.
Solutions for the Validation of Kryptofix 2.2.2 in [ 18 F]FECh
As matrix buffer PBS was used (pH 7.4). When necessary, pH was adjusted to pH 6.5 using a 10% solution of NaH 2 
Solutions for the Validation of Tetrabutylammonium in [ 18 F]FLT
TLC Procedure for Analysis of Kry
Spots of 2 µL samples were applied on silica plates by means of an Eppendorf micro pipette. It proved to be mandatory that the tip slightly touched the plate and allowed the liquid to drain slowly and penetrate the silica material without any active pressure from the pipette. Plates were immediately placed on a holder inside a glass chamber for 10 min above iodine (ca. 5 g) covering the complete bottom of the vessel, homogenously saturating the whole chamber with iodine vapor. Plates were photographed for documentation (PowerShot SX110 IS, macro mode; jpg files, Canon, Krefeld, Germany) and visually analyzed. All experiments were n = 3.
TLC Procedure for Analysis of TBA
Spots of 2 µL samples were applied on silica plates by means of an Eppendorf micro pipette, in analogy to Kry analysis, in addition it was essential that only two spots per plate were applied. Otherwise time was to long between first and last spot application and results were invalid. Spots needed to be ca. 10 mm from the edges of the plate. After drying of spots with a cool air stream (hair dryer) 10 µL of the MeOH/NH 4 OH solution were applied on each spot. Plates were then placed in the same iodine containing chamber as for Kry, for exactly 1 min. Afterwards, plates were photographed immediately for documentation and visually analyzed (before discoloration). All experiments were n = 3. The maximum volume in our case that could theoretically be injected in one patient is 20 mL, resulting in a calculated limit concentration of 110 mg/L. Our specification of <100 mg/L is more narrowly defined. For determination of the detection limit of the method additional solutions with concentrations from 3.1 to 125 mg/L were used. After staining with iodine, background on the plates showed an orange, light brown color. Spots of solutions containing Kry were dark brown with a diameter of 1-2 mm. In first experiments, the standard solution was prepared in WFI instead of citrate buffer. But it could be shown that as result spots were darker and of a smaller diameter. Therefore, Kry standard solutions are always prepared using buffer, to have most comparable conditions. Also, in preliminary tests it was shown that the intensity of the color of the Kry spot was dependent on the pH value of the test solution. At pH 5.0, intensity was lower than at higher pH. Therefore, buffers of standard solutions were adjusted to pH 5.0, representing the most unfavorable case. In general, content of residual Kry in [ 18 F]FDG solutions (>100 productions) was far below the limit of 100 mg/L.
Results and Discussion
Only in cases where pH of a solution was 6.0 or higher and the spot of the batch sample was of similar or higher intensity than the standard solution (100 mg/L; pH 5.0) there would be uncertainty. Then, the standard solution would need to be adjusted to the pH of this batch sample and the test to be repeated, to prove that Kry concentration of the batch solution was below the specified limit.
To test for the specificity of the method, [ From the same set of experiments the detection limit of the method was identified to be 6.25 mg/L, from a clearly visible spot. For proving the accuracy of the method, three types of spots were compared (Figure 1d) was applied. Experiments were again performed at pH 6.5 and 7.4, showing no pH dependence. In both cases spots 3 showed minimum coloration, spots 1 and 2 were of same intensity (Figure 2d ). Overall, validation was performed successfully, clearly demonstrating the feasibility of this TLC spot test. Stability of the standard solution to be used in routine quality control (100 mg/L Kry in PBS matrix buffer, pH 7.4), stored in 1 mL portions at <−15 °C was proven to be 6 months (three different batches; performance as in [ 18 F]FDG validation). (Figure 3b ). Comparison of spots from the series of concentrations showed that only differences in concentrations of ≥60 mg/L could be visualized definitely and also that only spots on the same plate were comparable due to plate individual results of staining (Figure 3c ). The spot from the standard solution of 40 mg/L of TBA was clearly visible and therefore this concentration was defined as detection limit (Figure 3c) Latter effect would lead to the necessity of pH adjustments of standard solutions for valid results of each batch in daily routine, but on the one hand residual Kry and also TBA concentrations close to the specified limits were never observed, normally they are not detectable-and detection limits are low.
On the other hand, in the investigated radiopharmaceuticals (all in buffered solutions) alterations in pH values were minimal (Table 1) . 
